摘要
目的:研究分析氯氮平片联合多巴丝肼片治疗帕金森病伴发精神障碍的临床效果。方法:将50例帕金森病伴发精神障碍患者随机分为常规组和研究组各25例,其中常规组予以奥氮平片联合多巴丝肼片,研究组予以氯氮平片联合多巴丝肼片。结果:研究组与常规组临床疗效、不良反应无明显差异(P>0.05);研究组用药后PANSS量表评分、UPDRS评分均低于常规组(P<0.05)。结论:多巴丝肼片与奥氮平联合可进一步改善帕金森病伴发精神障碍患者运动、精神功能,临床疗效确切,不良反应少。
Objective:To study the clinical effects of clozapine combined with Madopar in the treatment of Parkinson's disease with mental disorders.Methods:Fifty patients with Parkinson's disease and mental disorders were randomly divided into two groups.Among them,25 patients in the routine group received olanzapine tablets and Madopar treatment.The patients in the study group received clozapine tablets and Madopar treatment.Results:There was no difference in clinical efficacy and adverse reactions between the study group and the routine group(P>0.05).The PANSS score and UPDRS scores in the study group were lower than those in the routine group(P<0.05).Conclusion:The combination of Madopar and olanzapine can further improve the exercise and mental function of patients with Parkinson's disease and mental disorders,with exact clinical curative effect and few adverse reactions.
作者
王艳艳
Wang Yanyan(Taikang People's Hospital,Zhoukou 461400)
出处
《数理医药学杂志》
CAS
2021年第4期578-579,共2页
Journal of Mathematical Medicine
关键词
氯氮平片
多巴丝肼片
帕金森病
精神障碍
clozapine tablets
Madopar
Parkinson's disease
mental disorders
